Connecticut Bioscience Active Research
Several examples of active research projects conducted by established Connecticut Bioscience companies or organizations are the development of the Manoula Device by Lactation Innovations, the development of Shylicine by Vanessa Research, and EliV5's ongoing development of a drug that would be able to fight fungal pathogens.
Lactation Innovations — Overview, Focus, Incentives, Partnerships
- Lactation Innovations is currently in the midst of developing a technology that provides for more of an optimal breastfeeding experience for mothers.
- This project consists of the development of a medical device named The Manoula Device that conveniently and accurately informs providers and mothers "how much breast milk a baby has consumed." The that is then wirelessly shared through Bluetooth and infrared technology, providing mothers with data with vital knowledge.
- The project has gone through multiple stages of development. It has developed a proof of concept prototype as well as completed a preliminary subject and lab testing.
- Currently, it is waiting to get its utility patent approved. They are also conducting safety, prototyping and clinical testing. They are looking for FDA clearance and commercialization in 2023; this would allow for the device to be launched and made accessible to breastfeeding mothers and healthcare providers during that time period
- Lactation Innovations has partnered with Connecticut Children’s Office for Community Child Health; the latter has continued to support and advocate on the former's behalf. The Connecticut Children’s Office for Community Child Health looks forward to a continued partnership supporting children’s optimal healthy development."
- This company is hoping that pregnant women would view the decrease in maternal anxiety "regarding their infant’s nutritional intake and increase breastfeeding maintenance rates" as some of the incentives for them to opt for the product.
Vanessa Research — Overview, Focus, Incentives, Partnerships
- Vanessa Research, a biomedical company "driven by the desire to save children’s lives," is developing the first treatment for microvillus inclusion disease (MVID) with the aim of patients a chance to live a healthy life.
- Shylicine, marketed as "the first-ever investigational treatment developed for microvillus inclusion disease" is currently under development.
- The main objectives of the drug is to be able to "help the intestine absorb water and nutrients, reduce excessive secretion of ions and water, increase the absorptive surface of the intestine by restoring the villi and microvilli, and maintain the required integrity of the intestinal barrier."
- Vanessa Research has urged the public to participate in its Shylicine clinical trials, citing incentives such as the ability to help others and the privilege of being able to contribute to medical research.
- Over the past year, they have gained approval to conduct the second phase of clinical trials for the treatment of MVID.
- Vanessa Research strives to make an impact through collaboration in the form of partnerships. They described their partnerships as bringing technological, scientific, and entrepreneurial expertise, which allows everyone involved to mutually enhance the ability to make an impact on society. A few companies and/or organizations Vanessa Research have partnered with are BioCT, UCONN, ConnCat, The Garage, and CTNext.
- Currently, Shylicine is only limited to "investigational use only and is not available for sale."
EliV5 Therapeutics — Overview, Focus, Incentives, Partnerships
- EliV5 Therapeutics is currently developing new anti-fungal drugs to fight fungal pathogens.
- They have cited the public health crisis where invasive fungal infections are wreaking significant economic and healthcare burden as one of the factors as to why they are developing this novel antifungal drug.
- In a statement addressing the public health crisis, EliV5 Therapeutics said, "hospital patients who acquire invasive fungal infections experience longer hospital stays, increased morbidity, and higher mortality rates. Only a few classes of antifungal drugs are available, and the emergence of resistance within all classes is an alarming threat to global public health."
- One of the incentives the drug in development would procure is the overall improvement of patient treatment. According to EliV5, the clinical use of the drug "has the potential to provide a more effective therapeutic option for treating fungal infections and most importantly improving patient outcomes."
- EliV5 had recently submitted an application to Small Business Technology Transfer (STTR), a program that expands "funding opportunities in the federal innovation research and development (R&D) arena."
- They partnered with the Program for Innovative Therapeutics for Connecticut’s Health (PITCH), where the latter provided funding for the former's research project. Another organization that invested in the research initiatives of EliV5 is the Accelerator for Biosciences in Connecticut.